Prestige Biopharma Limited sell "PBP1510 (INN: Ulenistamab)"

Developed by Prestige Biopharma, PBP1510 (INN ulenistamab) is a first-in-class monoclonal antibody directed against pancreatic adenocarcinoma up-regulated factor (PAUF), a protein overexpressed in pancreatic adenocarcinoma that drives tumor growth, invasion, metastasis, immune evasion, and an immunosuppressive tumor microenvironment. By neutralizing PAUF, the antibody curbs its tumor-promoting effects in both cancer cells and the surrounding microenvironment. It holds Orphan Drug Designation from the FDA, EMA, and Korea's MFDS, plus FDA Fast Track status, and is in Phase 1/2a trials across the US, Europe, Asia, and Australia.